A study reports that Mounjaro (tirzepatide), a medication used for type 2 diabetes and weight loss, is associated with a lower risk of heart attacks in people who have both type 2 diabetes and existing heart disease. According to the reports, participants treated with Mounjaro experienced about a 33% reduction in heart attack occurrence compared with people receiving another type of type 2 diabetes medication. The findings are described as the first time the drug has been shown to reduce heart attack risk in this specific way, based on the results of the comparative analysis. Across the articles, researchers present the main figure consistently: patients on Mounjaro are described as being roughly one-third less likely to suffer a heart attack than those on the alternative medication. The coverage emphasizes the link between the treatment and improved cardiovascular outcomes, while the reported information focuses on comparative risk rather than detailing exact study design elements or broader endpoints beyond heart attacks.